MHRA Proposes Accelerated Pathway for Rare Disease Therapies

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has opened a public consultation on a new regulatory framework intended to accelerate development of therapies for ultra-rare diseases. The proposal introduces a flexible approval pathway called the Investigational Marketing Authorisation (IMA), combining clinical trial clearance with a progressive route toward market authorization.

The proposed Rare Disease Therapies Regulatory Framework marks a major shift in how the UK could evaluate therapies for conditions affecting extremely small patient populations. The MHRA said the model would support earlier patient access to promising treatments while maintaining long-term safety, efficacy, and quality oversight.

Addressing Longstanding Barriers in Rare Disease Development

Rare diseases affect an estimated 3.5 million people in the UK, yet fewer than 5% of conditions currently have an approved therapy. Diagnostic delays often exceed five years, while nearly 30% of affected children die before age five.

Traditional drug development pathways rely on large, statistically powered clinical trials that are often impossible in diseases affecting fewer than one in 50,000 people. Limited patient numbers, fragmented natural history data, and high development costs have left many rare disease programs commercially unviable.

The MHRA’s proposal introduces a risk-proportionate, iterative evidence-generation model tailored to ultra-rare conditions. Under the IMA pathway, patients could gain earlier access to investigational therapies while regulators continue monitoring accumulating clinical and real-world evidence.

Regulatory Shift Toward Adaptive Development Models

The proposal reflects a broader regulatory shift toward adaptive development pathways and greater use of real-world evidence in rare diseases. The MHRA’s model places stronger emphasis on continuous evidence generation, patient registries, and collaboration between regulators, academic centers, healthcare systems, and developers.

NICE would continue overseeing reimbursement and NHS adoption decisions, creating a dual framework that combines accelerated regulatory access with evidence-based health technology assessment.

Lower Development Costs Could Improve Commercial Viability

The MHRA expects the compressed regulatory pathway to reduce development timelines and improve the commercial viability of ultra-rare disease programs. The framework was developed alongside the Rare Disease Consortium, which includes patient organizations, biotech companies, academic institutions, and healthcare stakeholders.

Genetic Alliance UK said the initiative could expand incentives for therapies targeting lower-prevalence diseases. Cell and Gene Therapy Catapult highlighted the framework’s relevance for advanced therapies, where iterative evidence collection often aligns more closely with emerging science than conventional trial structures.

Stakeholders Back the Proposal

Former UK Prime Minister David Cameron, now Chair of the Oxford-Harrington Rare Disease Centre Advisory Council, described the initiative as “an important and hopeful step” for families affected by rare genetic diseases.

Patient advocacy groups and research organizations also welcomed the consultation, noting the potential to reduce diagnostic delays and accelerate access to potentially life-saving therapies.

 Consultation Open Through July 2026

The MHRA consultation remains open until July 30, 2026, with feedback invited from patients, clinicians, researchers, caregivers, industry stakeholders, and the wider public.

If implemented, the framework could position the UK as a leading regulatory hub for rare disease innovation by enabling earlier patient access while preserving long-term safety and evidence standards.

Reference

Landmark new plans bring treatments for rare diseases a step closer – GOV.UK